Azenta (AZTA) shares ended the last trading session 7.2% higher at $49.65. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 13.2% gain over the past four weeks.Azenta scored a strong price increase driven by investors’ optimism following the news of the company joining the S&P SmallCap 600. Per S&P Dow Jones’ press release, Azenta replaced Envestnet Inc. in the S&P SmallCap 600 effective from November 25. Additional ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For fiscal year ended September 30, 2024 or ☐ | --- | --- | --- | |---------------------------------------------------------------------------------------------------------|----------------------|-----------------------------------------------------| | TRANSITION REPORT PURSUANT TO OF THE SECURITIES EXCHANGE \nFo ...

BURLINGTON, Mass., Nov. 14, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in Stephens Annual Investment Conference, on Wednesday November 20, 2024, which includes a presentation beginning at 1:00 pm CT. The live webcast can be accessed through the Azenta investor relations website at https://investors.azenta.com/events. A replay of the webcast will be available following the event.About Azenta Life SciencesAzenta, Inc. (Nasdaq: AZTA) is a leading p ...

Azenta, Inc. (NASDAQ:AZTA) Q4 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Yvonne Perron - Vice President, FP&A and Investor Relations John Marotta - President and Chief Executive Officer Herman Cueto - Executive Vice President and Chief Financial Officer Conference Call Participants David Saxon - Needham & Company Vijay Kumar - Evercore ISI Jacob Johnson - Stephens Andrew Cooper - Raymond James Matt Stanton - Jefferies Lucas Baranowski - KeyBanc Capital Operator Greetings ...

Azenta (AZTA) came out with quarterly earnings of $0.18 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.13 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 63.64%. A quarter ago, it was expected that this supplier to semiconductor manufacturers would post earnings of $0.07 per share when it actually produced earnings of $0.16, delivering a surprise of 128.57%.Over the last fou ...

Exhibit 99.1 Azenta Reports Fourth Quarter and Full Year Fiscal 2024 Results; Announces the Plan to Sell B Medical Systems and Appoints Lawrence Y. Lin as CFO ● FY'24 revenue growth of 4%, reported and organic, in combined Sample Management Solutions and Multiomics ● FY'25 organic revenue growth expected to be 3% to 5% year over year, with Adjusted EBITDA margin expansion of approximately 300 basis points ● Pursuing a sale of B Medical Systems to simplify portfolio and drive revenue growth and profitability ...

FY'24 revenue growth of 4%, reported and organic, in combined Sample Management Solutions and Multiomics FY'25 organic revenue growth expected to be 3% to 5% year over year, with Adjusted EBITDA margin expansion of approximately 300 basis points Pursuing a sale of B Medical Systems to simplify portfolio and drive revenue growth and profitability Announces appointment of Lawrence Y. Lin as Chief Financial Officer; Herman Cueto to remain as advisor to ensure smooth transitionBURLINGTON, Mass., Nov. 12, 2024 ...

BURLINGTON, Mass., Nov. 4, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) will announce fiscal fourth quarter and full year 2024 earnings which ended on September 30, 2024, on Tuesday, November 12, 2024, after the market closes.The Company will host a conference call and live webcast to discuss its financial results on the same day, Tuesday, November 12, 2024, at 4:30 p.m. Eastern Time. Analysts, investors and members of the media can access the live webcast via the Azenta website at https://investors.aze ...

BURLINGTON, Mass., Oct. 30, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced the launch of a long-read Whole Genome Sequencing (WGS) test for clinical applications. Azenta becomes the first commercial provider to obtain regulatory approval to offer this test in the United States. Traditional short-read sequencing methods often struggle with identifying genetic variants in repetitive regions of the genome that underpin many rare diseases, hindering accurate diagnoses and targeted treatments. ...

Succeeds Dr. Stephen Schwartz Following 14-Year TenureBURLINGTON, Mass., Sept. 4, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) ("Azenta" or "the Company"), today announced that John P. Marotta will join the Company as President and CEO effective September 9, 2024, succeeding Dr. Stephen Schwartz, who is retiring following a distinguished tenure. Dr. Schwartz will remain as an advisor to Azenta to ensure a smooth and successful transition. Mr. Marotta has two decades of experience leading global companie ...